MindMed
MNMD
About: Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Employees: 74
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
58% more call options, than puts
Call options by funds: $6.9M | Put options by funds: $4.38M
14% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 49
13% more capital invested
Capital invested by funds: $240M [Q1] → $271M (+$30.5M) [Q2]
0.71% more ownership
Funds ownership: 54.59% [Q1] → 55.3% (+0.71%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
5% less funds holding
Funds holding: 188 [Q1] → 178 (-10) [Q2]
37% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 27
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Oppenheimer
Jay Olson
|
$25
|
Outperform
Reinstated
|
4 Aug 2025 |
|
Chardan Capital
Rudy Li
|
$20
|
Buy
Maintained
|
1 Aug 2025 |
Financial journalist opinion
Based on 3 articles about MNMD published over the past 30 days
